In the tumor microenvironment, trastuzumab induces abnormal production of TGF-β and IFN-γ, which subsequently enhances the HLA-G/KIR2DL4 signaling pathway, where HLA-G is the sole ligand for KIR2DL4 (41). The gene discussed is KIR2DL4; the disease is neoplasm.